La paradoja del Premio Nobel: premios Nobel, no premios nobles / Nobel Prize paradox: Nobel Prize, not a noble prize

El Premio Nobel es uno de los premios más deseados en ciencia y más conocidos en la sociedad. Sin embargo, su reputación no está exenta de complejidades, incluidas las limitaciones para los galardonados y los prejuicios en las nominaciones. Navegar por el delicado equilibrio entre el reconocimiento y los impactos concretos de las contribuciones premiadas debería ofrecer una idea de la importancia del premio más allá del mero prestigio y su valor monetario. Si bien otros premios pueden presumir de mayores recompensas financieras, a menudo carecen del mismo nivel de prestigio. La inclusión de figuras públicas como galardonadas y la amplia cobertura mediática en torno al Premio Nobel elevan aún más su importancia percibida, aunque esto podría ocultar una realidad más matizada. Asimismo, las asociaciones positivas vinculadas al nombre «Nobel» que se asemejan al adjetivo «noble» pueden realzar el prestigio del premio. Esta sutil conexión con la «nobleza» añade una capa de honor y distinción al premio, contribuyendo a su importancia y prestigio percibidos. Además, la sobrerrepresentación de premios Nobel de países específicos provoca un escrutinio sobre el cumplimiento del testamento del Nobel, que prioriza las contribuciones al bienestar global. Esta discrepancia plantea dudas sobre la inclusión y el impacto global del premio.(AU)

The Nobel Prize is one of the most sought-after awards in science and society. However, its reputation is not without complexities, including constraints on laureates and biases in nominations. Navigating the delicate balance between recognition and the tangible impacts of awarded contributions should offer insight into the Prize's significance beyond mere prestige and monetary value. While other awards may boast higher financial rewards, they often lack the same level of prestige. The inclusion of public figures as laureates and the extensive media coverage surrounding the Nobel Prize may further elevate its perceived importance, though this may hide a more nuanced reality. Additionally, the positive associations linked to the name “Nobel” resembling the adjective “noble” can enhance the award's prestige. This subtle connection to “nobility” adds a layer of honor and distinction to the Prize, contributing to its perceived significance and prestige. Moreover, the overrepresentation of Nobel laureates from specific countries prompts scrutiny over the fulfillment of Nobel's testament, which prioritizes contributions to global well-being. This discrepancy raises questions about the inclusivity and global impact of the Prize.(AU)

Nobel Prize paradox: Nobel Prize, not a noble prize.

The Nobel Prize is one of the most sought-after awards in science and society. However, its reputation is not without complexities, including constraints on laureates and biases in nominations. Navigating the delicate balance between recognition and the tangible impacts of awarded contributions should offer insight into the Prize's significance beyond mere prestige and monetary value. While other awards may boast higher financial rewards, they often lack the same level of prestige. The inclusion of public figures as laureates and the extensive media coverage surrounding the Nobel Prize may further elevate its perceived importance, though this may hide a more nuanced reality. Additionally, the positive associations linked to the name "Nobel" resembling the adjective "noble" can enhance the award's prestige. This subtle connection to "nobility" adds a layer of honor and distinction to the Prize, contributing to its perceived significance and prestige. Moreover, the overrepresentation of Nobel laureates from specific countries prompts scrutiny over the fulfillment of Nobel's testament, which prioritizes contributions to global well-being. This discrepancy raises questions about the inclusivity and global impact of the Prize.

Advances in heart failure management. / Avances en insuficiencia cardiaca.

Heart failure is a pathological condition characterized by substantial prevalence and mortality, particularly in the Western world. Over recent decades, both pharmacological and non-pharmacological interventions have emerged, significantly enhancing patient survival and overall quality of life. Moreover, advancements in diverse imaging modalities facilitate precise diagnosis and comprehensive investigation into the fundamental etiology, enabling the development of more precise therapeutic approaches. Nonetheless, discernible gaps persist in comprehending specific facets of this condition, albeit persistent research endeavors seek to elucidate these inquiries.

A Feasibility and Safety Study of a Novel Human Decellularized Dermal Matrix to Accelerate Healing of Neuropathic Diabetic Foot Ulcers in People With Type 1 and Type 2 Diabetes.

OBJECTIVES: The purpose of this study was to determine the feasibility and safety of a novel decellularized dermal matrix (DDM) for the treatment of chronic diabetic foot ulcers (DFUs). METHODS: An interventional, single-arm, prospective study of DDM for DFU treatment was conducted in 2 Canadian centres from July 1, 2016 to May 30, 2017. Individuals ≥18 years of age, with an active DFU of ≥2 weeks and ulcer area ≥1 cm2 before debridement and who consented to participate, were enrolled in this clinical trial. RESULTS: A total of 11 patients were enrolled, with 9 patients (82%) having achieved 100% closure between 2 and 8 weeks. The mean and median times to wound closure for these patients were 3.3 and 2.5 weeks, respectively. The mean and median reductions in wound area at 4 weeks posttreatment were 87% and 100%, respectively. The proportion of patients having achieved complete healing at 12 weeks was 82%. All patients received only 1 DDM application to achieve these results. There were no adverse events related to use of the product. No cases of recurrence during a 1-year follow up after completion of the study were reported for patients who achieved wound closure. CONCLUSIONS: These findings provide evidence that this DDM may be safe and effective for the treatment of chronic, hard-to-heal neuropathic DFUs. Specifically, DDM demonstrated the potential to accelerate healing of DFUs when compared with reported times of 8 to 12 weeks required to achieve closure using the current standard of care.

Nuevos avances en cirugía hepática: evaluación y planificación preoperatoria (Parte 1) / New advances in liver surgery: evaluation and preoperative planning

Resumen Los avances en la cirugía hepática de los últimos años han permitido resecciones hepáticas más extensa y complejas para el tratamiento de diferentes patologías del hígado sin un aumento excesivo de la morbimortalidad perioperatoria. El desarrollo de diferentes técnicas, tecnologías y herramientas para la evaluación preoperatoria han mejorado la planificación quirúrgica con el uso por ejemplo de las tecnologías audiovisuales e impresión de modelos en 3 dimensiones (3D) de alta fidelidad. Otros avances, han permitido realizar una mejor evaluación funcional del parénquima hepático y una caracterización más precisa de las lesiones con el uso por ejemplo de verde de indocianina, cintigrafía hepática y resonancia magnética con contraste hepatoespecífico. Este artículo describe algunos de los nuevos avances en la evaluación y planificación preoperatoria en cirugía hepática.

Advances in liver surgery in recent years have made it possible to achieve more extensive and complex liver resections for the treatment of different liver diseases without an excessive increase in perioperative morbidity and mortality. The development of different techniques, technologies and tools for preoperative evaluation have improved surgical planning with the use, for example, of audiovisual technologies and printing of high-fidelity 3-dimensional (3D) models. Other advances have allowed a better functional evaluation of the liver parenchyma and a more precise characterization of the lesions with the use, for example of indocyanine green or liver scintigraphy and magnetic resonance with hepatospecific contrast. This article describes some of the new advances in preoperative evaluation and planning in liver surgery.

Análise do Impacto Orçamentário da Prevenção de Lesão por Pressão em Idosos Acamados / Analysis of the Budgetary Impact of Pressure Injury Prevention in Bedridden Elderly / Análisis del Impacto Presupuestario de la Prevención de Lesiones por Presión em Ancianos Encamados

Objetivo: Analisar o impacto orçamentário e o incremento de custos da incorporação de superfícies especiais para o manejo da pressão para prevenção de lesão por pressão em pacientes idosos acamados. Método: Análise de impacto orçamentário, seguindo as recomendações da diretriz metodológica análise de impacto orçamentário. Delinearam-se dois possíveis cenários (referência e alternativo 1, 2 e 3). Resultados: O custo em cinco anos no cenário de referência, adotando apenas a estratégia de mudança de decúbito, foi estimado em R$ 253.86,2542,81. Os custos nos cenários alternativos 1, 2 e 3 foram respectivamente, no mesmo período e com os ajustes econômicos, R$ 250.422.191,73, R$ 249.223.263,19 e R$ 248.029.130,37. Conclusão: A utilização de altas tecnologias nem sempre será o diferencial para o melhor desfecho clínico do paciente e poderá acarretar mais custo ao sistema.

Objective:To analyze the budgetary impact and the increase in costs of the incorporation of special surfaces for pressure management to prevent pressure injuries in bedridden elderly patients. Method: Budget impact analysis, following the recommendations of the budget impact analysis methodological guideline. Two possible scenarios were out lined. In the first (alternative) scenario, the elderly receives a prevention strategy that includes the use of a viscoelastic mattress as a pressure distribution surface and a change in position with a minimum interval of 2 hours. In the second scenario (reference), the elderly receives a prevention strategy that only includes a change in position with a minimum interval of 2 hours. All costs were estimated using the macro costing technique. Results: The results of the analysis of the budget impact speak in disfavor, therefore, contrary to the eventual incorporation of the viscoelastic mattress as a complementary strategy to the systematic change of decubitus, of at least every 2 hours as a measure to prevent pressure injuries. Conclusion: The use of high technologies will not always be the differential for the best clinical outcome of the patient and it can result in more cost to the system.

Objetivo:Analizar el impacto presupuestario y el incremento de costes de la incorporación de superfícies especiales para el manejo de la presión para la prevención de lesiones por presión em pacientes ancianos encamados. Método:Análisis de Impacto Presupuestario (AIO), siguiendo las recomendaciones de la Guía Metodológica de Análisis de Impacto Presupuestario. Se esbozaron dos escenarios posibles. Em el primer escenario (alternativo), las personas mayores recibe ecnologiategia de prevención que incluye el uso de um colchón viscoelástico ecnologiaficie de distribución de presiem y un cambio de poemión con un intervalo mínimo de 2 horas. Enel segundo escenario (referencia), los adultos mayore ecnologiana estrategia de prevención que solo incluye el cambio de posición conun intervalo mínimo de 2 horas. Todos los costos se estimaron utilizando la técnica de macro costos. Resultados: Los resultados del análisis de impacto presupuestario hablan desfavorablemente, por tanto, en contra de la eventual incorporación del colchón viscoe ecnologiamo estrategia complementaria al cambio sistemático de decúbito, de al menos cada 2 horas como medida de prevención de lesiones por presión. Conclusión: Se concluye que el ecnologiass tecnologías no siempre será el diferencial para el mejor desenlace clínico del paciente y que puede resultar em mayor costo para el sistema.

Nuevo algoritmo de test genéticos para evaluación de trastornos del neurodesarrollo / New genetic testing algorithm for evaluation of neurodevelopmental disorders

Resumen En más de la mitad de los trastornos del neurodesarrollo se demuestra una etiología genética. La detección de estas variantes patogénicas tiene un impacto enorme en el curso de la enfermedad de estos pacientes. Permite la aceptación de la enfermedad por parte de los padres de los pacientes, emitir un pronóstico, adelantarnos a las futuras consecuencias de la enfermedad y, en cada vez más casos, instaurar un tratamiento o cambiar el ya establecido. Las técnicas genéticas que permiten estos diagnósticos etiológicos son muy jóvenes y por lo tanto todavía no totalmente asumidas por los neuropediatras. Incluso en las guías de diag nóstico de las diferentes sociedades científicas, sus algoritmos están desfasados por la rápida incorporación de nuevas técnicas. En este artículo se revisan las técnicas actuales así como los últimos avances en las mismas, que se están incorporando a la práctica clínica.

Abstract In more than half of neurodevelopmental disorders, a genetic etiology is demonstrated. The detection of these pathogenic variants has a huge impact on the course of the disease of these patients. It allows the acceptance of the disease by the parents of the patients, issue a prognosis, anticipate the future consequences of the disease and in more and more cases establish a treatment or change the one already established. The genetic techniques that allow these etiological diagnoses are very recent therefore not yet fully assumed by neuropediatricians. Even in the diagnostic guides of the different scientific societies, their algorithms are outdated by the quick incorpora tion of new techniques. This article reviews the current techniques as well as the latest advances in them that are being incorporated into clinical practice.

Novedades del glaucoma en tiempos de COVID-19 / News about glaucoma in the time of COVID-19

El impacto de la COVID-19 en la atención médica dominó las noticias en 2020, incluida la atención del glaucoma. Sin embargo, el reciente cambio de paradigma en la terapia de esta patología hacia una intervención más temprana, un mejor manejo del cumplimiento del paciente y un nuevo enfoque en abordar la patología real, continuó avanzando en este periodo con la aprobación de nuevos medicamentos, productos biológicos y dispositivos, que significaron avances en la atención médica. En este artículo, pretendemos reflexionar sobre los logros obtenidos en el año 2020 en el tratamiento del glaucoma, así como brindar una descripción general de los hallazgos más notables. Se realizó una búsqueda sistemática de la literatura científica de mayor impacto. Se limitó la búsqueda por tipo de diseño (revisiones, series de casos, estudios descriptivos, analíticos y experimentales, metanálisis). No se tuvo en cuenta el idioma de la publicación(AU)

The impact of COVID-19 on medical care was ever-present in the news during the year 2020, and glaucoma care was not an exception. However, the recent paradigm switch in the treatment of this condition towards earlier intervention, better management of patient compliance, and a new approach in addressing the actual disorder, continued to gain ground in this period with the approval of new drugs, biological products and devices leading to the advancement of medical care. The purpose of the study was to reflect on the progress achieved in the treatment of glaucoma in the year 2020, and provide a general description of the most notable findings. A systematic search was conducted in the highest-impact scientific literature. The search was limited to reviews, case series, descriptive, analytical and experimental studies, and meta-analyses. The language of publication was not taken into account(AU)

[Pediatric Palliative Care - When the End Comes with the Beginning]. / Pädiatrische Palliative Care ­ wenn das Ende mit dem Anfang kommt.

Pediatric Palliative Care - When the End Comes with the Beginning Abstract. Palliative care is not usually associated with childhood and adolescence. Nevertheless, in German-speaking Europe alone, more than 50 000 children live with life-shortening illnesses, and about 5000 children die every year. Palliative care for children and adolescents (PPC) is an attitude that must not be forced on anyone, but must be lived; and, in the case of complex-chronic diseases often over many years. A successful and sustainable implementation of PPC is therefore based on an appreciative collaboration between different teams and the affected families, true to the quadriga presented here of comprehensive symptom control with curiosity, patience, activity and humility. Necessary basics such as the care plan, interprofessional home visits and the round table, plus 24-hour accessibility, are here presented, as well as a triage technique and the advanced care management.

La hepatitis viral y los métodos dialíticos / Viral hepatitis and the dialytic methods

RESUMEN Se realizó un acercamiento teórico al problema actual de la hepatitis viral y los métodos dialíticos -desde el enfoque de la ciencia, la tecnología y la sociedad-, con el objetivo de resaltar la importancia de su prevención en los pacientes de riesgo. Se analizó cómo el desarrollo alcanzado por la ciencia, en particular en el campo de la Medicina, y el enorme avance tecnológico, permiten el empleo de medidas de soporte vital, como los métodos dialíticos de depuración extrarrenal. Pero, con ello, existe el alto riesgo de transmisión de la hepatitis como infección nosocomial, problema social al que urge buscar soluciones (AU).

ABSTRACT The authors theoretically approached the current problem of viral hepatitis and the dialytic methods -from the point of view of science, technology and society-, with the objective of pointing up the importance of its prevention in risk patients. They analyzed how the great development of the science, particularly in the field of medicine, and the enormous technological advance allow the usage of life support measures, like the dialytic methods of extra renal depuration. But, it involves a high risk of hepatitis transmission as nosocomial infection, a social problem that has to be urgently solved (AU).

[Borderline Ovarian Tumours: CNGOF Guidelines for Clinical Practice - Surgical Management of Advanced Stages of Borderline Ovarian Tumours]. / Tumeurs frontières de l'ovaire. Recommandations pour la pratique clinique du CNGOF ­ prise en charge chirurgicale des stades avancés des tumeurs frontières de l'ovaire.

OBJECTIVE: To evaluate the surgical management of borderline ovarian tumors (BOT) in the framework of recommendations for clinical practice made by the National College of Obstetricians and Gynecologists (CNGOF) METHODS: This is a comprehensive review of the literature on the advanced stages of BOT. Bibliographic selection was conducted in PubMed from 2007 to 2019 inclusive, selecting publications in English and French. Articles were selected on the basis of the title, then the abstract and finally the full article. The levels of evidence of the studies were defined according to the scale proposed by the High Authority of Health (HAS). RESULTS: By analogy with epithelial ovarian cancer, in case of preoperative suspicion or after a postoperative diagnosis of advanced BOT, the patient must be referred to an expert centre in ovarian cancer (gradeC). There is no data from the literature to conclude that a hysterectomy should be performed routinely, however, the goal in the advanced stages of BOT is no tumor residue (gradeC). In advanced stages of BOT, systematic lymphadenectomy is not recommended, but excision of suspected lymph node on preoperative and intraoperative evaluation, for curative purposes, may be discussed to obtain no residual disease (gradeC). It is recommended to describe peritoneal carcinomatosis before any excision as well as tumor residues at the end of surgery (grade B). The use of a peritoneal carcinomatosis score to evaluate tumor burden such as the "Peritoneal Carcinosis Index" (PCI) is recommended (gradeC). For advanced stages of BOT, a conservative treatment with at least the preservation of the uterus and an ovarian fragment in a patient wishing a pregnancy may be proposed after Multidisciplinary Concertation Meeting (GradeC). Contralateral ovary biopsy is not recommended in advanced stage BOT (GradeC) but restaging surgery associated with removal of all tumor lesions is recommended when not performed initially (GradeC). It is not possible to make a recommendation on chemotherapy indication in advanced stages even with invasive implants. CONCLUSION: The weakness of the literature and the retrospective nature of BOT advanced stage studies limit the grade of the recommendations.

Visión reflexiva del desarrollo tecnológico en la salud / Reflective vision of technological development in health

La vida del hombre en la actualidad, no puede concebirse sin los avances de la ciencia y la técnica que tuvieron lugar entre los siglos XVIII y XX. Cada día se invierte más en el desarrollo de la ciencia y la tecnología. Desde la óptica de la profesión médica, interesa el constante desarrollo científico que permita mejorar la salud de la población. Sin embargo, debe ser una preocupación, los perjuicios a la salud de los individuos que representa el desarrollo tecnológico. Se llevó a cabo un análisis bibliográfico y documental, con el objetivo de valorar los efectos negativos para la salud humana, de los avances científico- técnicos, específicamente en Cuba. El uso indiscriminado de los avances científico-tecnológicos puede dañar la salud y el abuso de estos, puede dar al traste con la vida del hombre(AU)

The life of man today, cannot be conceived without the advances of science and technology, which took place between the eighteenth and twentieth centuries. Every day more is invested in the development of science and technology. From the perspective of the medical profession, interested in the constant scientific development, to improve the health of the population. However, it must be a concern, the damages to the health of the individuals that represent the technological development. A bibliographic and documentary analysis was carried out, with the objective of assessing the negative effects for human health, of scientific and technical advances, specifically in Cuba. The indiscriminate use of scientific-technological advances can damage the health and abuse of these, can ruin the life of man(AU)

Avances en la aplicación de la ciencia y la técnica en la oftalmología cubana y sus desafíos actuales / Advances in the application of sciences and technology in Cuban Ophthalmology and its current challenges

RESUMEN Cuba ha demostrado en todas las épocas, la grandeza de sus científicos, los avances y logros realizados por ellos. Ya desde los inicios de 1830 se comenzaba a hablar de adelantos en la oftalmología cubana. Desde ese momento nuestros científicos tenían presente el pensamiento filosófico en función de la investigación científica para lograr una tecnología de punta en la especialidad. Al triunfo de la revolución, en 1959, el desarrollo de la oftalmología era casi desconocido. En el presente siglo los servicios oftalmológicos del país disponen de todo lo indispensable para hacer frente al desafío que se avecina constantemente con la tecnología. La Misión Milagro, el mejor ejemplo del conocido impacto de los avances y prestigio de oftalmología en Cuba y otros países, permite afirmar que esta tecnociencia abarata los tratamientos y la atención a los pacientes con independencia de sus estados económicos. Cuba ha demostrado que no solo el capital monetario es importante para el desarrollo social, pues el capital humano eleva la sociedad a nuevas dimensiones. En esto consiste el impacto político de la población, beneficiada por los avances revolucionarios en la oftalmología cubana (AU).

SUMMARY Through the times, Cuba has showed the greatness of its scientists and their advances and achievements. So early as from the beginning of 1830 there were commentaries on the advances in Cuban Ophthalmology and from those times Cuban scientists put the philosophic thought in function of the scientific research to accede to latest technology in the specialty. At the triumph of the Revolution in 1959, the development of Ophthalmology was almost inexistent, but in the current century the ophthalmological services of the country have the essential to affront the constant challenge of new technologies. The results of Mision Milagro, (Miracle Mission, the program organized by Cuban Government to heal ophthalmologic diseases in other countries like Venezuela, Ecuador and others) allow us to affirm that techno-sciences reduce the costs of the patients' treatment and care regardless of their economic status. Cuba has showed that not only the monetary capital is important for the social development: human capital raises society to new dimensions. That is the political impact on the population benefited by the revolutionary advances in Cuban Ophthalmology (AU).

Avances en el tratamiento de la distrofia de Duchenne / Advances in the treatment of Duchenne muscular dystrophy

La distrofia muscular de Duchenne es una enfermedad genéticamente determinada, ligada al cromosoma X y caracterizada clínicamente por producir debilidad muscular progresiva, con una incidencia de 1 por cada 3500-6000 varones nacidos. Es causada por la mutaciones en el gen DMD, el cual codifica la distrofina, una proteína sub-sarcolémica esencial para la estabilidad estructural del músculo. Los defectos genéticos en el gen DMD, se dividen en: deleciones (65%) duplicaciones (5-10%) y mutaciones puntuales (10-15%). Actualmente no se dispone de tratamiento curativo, el único fármaco que ha demostrado modificar la historia natural de la enfermedad (independientemente de la mutación genética) son los corticoides, los cuales están indicados en estadios tempranos de la enfermedad. En relación a los ensayos clínicos, en los últimos diez años se han experimentado grandes avances en el campo de las opciones terapéuticas, divididos en dos grandes dianas terapéuticas: 1) el área de las terapias génicas y 2) tratar de revertir o bloquear los procesos fisiopatológicos de la enfermedad, tales como inflamación, fibrosis, regeneración muscular, etc. Es probable que un tratamiento eficaz para la distrofia muscular de Duchenne requiera combinaciones que se apliquen tanto al defecto primario como las consecuencias fisiopatológicas secundarias.

Duchenne muscular dystrophy is a genetically determined disease, linked to the X chromosome, c haracterized clinically by producing progressive muscle weakness, with an incidence of 1 per 3500-6000 males born. It is caused by the mutation of the DMD gene, which encodes dystrophin, a sub-sarcolemmal protein essential for structural muscle stability. The genetic defects in the DMD gene are divided into: deletions (65%) duplications (5.10%) and point mutations (10-15%). At present there is no curative treatment, the only drug that has been shown to modify the natural history of the disease (independently of the genetic mutation) are corticosteroids, currently indicated in early stages of the disease. In relation to clinical trials, in the last ten years, has experienced great advances in the field of therapeutic options, divided into two major therapeutic targets: 1) the area of gene therapies and 2) trying to reverse or block the pathophysiological processes of the disease, such as inflammation, fibrosis, muscle regeneration, etc. It is likely that an effective treatment for Duchenne muscular dystrophy requires combinations of therapies that address both the primary defect and its secondary pathophysiological consequences.

Insuficiencia cardíaca: desafíos en la terapia farmacológica / Heart failure: challenges in pharmacological therapy

La Insuficiencia Cardíaca (IC) es una entidad clínica de gran importancia, por su elevada incidencia y mortalidad, por ende la inquietud de realizar constantes y actualizadas revisiones para optimizar su tratamiento y así impactar la morbimortalidad de los pacientes. Objetivo: analizar críticamente la literatura médica, en el tratamiento farmacológico de la insuficiencia cardíaca para ofrecer una mejor calidad de vida al paciente. Métodos: investigación documental a través de la revisión sistemática de artículos primarios en revistas científicas en bases de datos bibliográficas en ciencias de la salud: Pub Med, Google Académico, Elsevier, ScienceDirect, Biblioteca Virtual en Salud (BVS) OPS y Scielo, entre los años de 2014 y 2018, para ello se determinaron los siguientes descriptores: insuficiencia cardiaca, tratamiento, desafíos, calidad de vida. Se revisaron 28 artículos digitales actualizados y cotejados. Resultados: En el tratamiento actual de la insuficiencia cardiaca, prevalece la combinación Sacubitril/Valsartán, ya que disminuye el riesgo de muerte cardiovascular en un 20% y de hospitalización en 21%; además, disminuye los efectos adversos en relación al tratamiento convencional con (IECA). Conclusión: Las nuevas terapias farmacológicas en insuficiencia cardíaca, permiten sustituir las terapias convencionales y optimizar calidad de vida(AU)

Heart Failure (HF) is a clinical entity of great importance, due to its high incidence and mortality, therefore the concern of conducting constant and updated reviews to optimize their treatment and thus impact the morbidity and mortality of patients. Objective: to critically analyze the medical literature, in the pharmacological treatment of heart failure to offer a better quality of life to the patient. Methods: documentary research through the systematic review of primary articles in scientific journals in bibliographic databases in health sciences: Pub Med, Google Scholar, Elsevier, ScienceDirect, Virtual Health Library (VHL) PAHO and Scielo, among the years of 2014 and 2018, for this the following descriptors were determined: heart failure, treatment, challenges, quality of life. 28 updated and collated digital articles were reviewed. Results: In the current treatment of heart failure, the Sacubitril / Valsartan combination prevails, since it reduces the risk of cardiovascular death by 20% and hospitalization by 21%; In addition, it reduces adverse effects in relation to conventional treatment with (ACEI). Conclusion: the new pharmacological therapies in heart failure, allow to replace conventional therapies and optimizing quality of life(AU)

Avances en la atención de salud a los pacientes con enfermedades reumáticas / Advances in health care in rheumatoid diseases

Introducción: Las enfermedades reumáticas, debido a su evolución natural, provocan afectaciones a la calidad de vida de las personas afectadas por eso es de vital importancia el diagnóstico temprano, el tratamiento oportuno y la prevención. El conocimiento de los adelantos contemporáneos en la atención de salud es una herramienta que ayuda a tomar decisiones clínicas en la práctica diaria, aunque la decisión final sobre el diagnóstico y el tratamiento de un paciente determinado dependerá de las características particulares de cada uno. Objetivo: Discutir algunos avances en la atención de salud a los pacientes con en enfermedades reumáticas. Desarrollo: Debido a que en la práctica clínica se encuentran con frecuencia resultados discordantes, la actualización de temas como este permite socializar los resultados obtenidos con profesionales del gremio, mostrar las estrategias más efectivas o los mejores métodos para el diagnóstico precoz, tratamiento y cuidado de estas enfermedades sobre la base de experiencias asistenciales e investigativas en varias regiones del mundo o en contextos diferentes. Conclusiones: Para controlar mejor las enfermedades reumáticas se necesita una estrategia organizativa en el marco de la cual se aprovechen las fortalezas de la prevención primaria, secundaria y terciaria y que los profesionales, de acuerdo con sus conocimientos y competencias, lleven a cabo acciones que prevengan las graves complicaciones de estas enfermedades. En varios estudios clínicos y ensayos terapéuticos se trabaja con novedosos fármacos biológicos, donde se evalúa su efectividad, se identifican los efectos adversos y se valora la relación riesgo-beneficio(AU)

Rheumatic diseases, due to their natural evolution, bring with them effects on the quality of life of the people carrying this conditions, which is why their early diagnosis, timely treatment and prevention are of vital importance. The knowledge of contemporary advances in health care is a tool to help when making clinical decisions in daily practice, although the final decision on the diagnostic or therapeutic approach of a specific patient will depend on the characteristics of the same. Objective: to discuss some advances in health care in rheumatoid diseases. Development: due to the fact that in clinical practice discordant results are frequently found, the updating of topics such as these allows to socialize the results obtained with professionals of the guild, to show the most effective strategies or the best methods for the early diagnosis, treatment and management of these diseases, on the basis of assistance and research experiences in various regions of the world or in different contexts. Conclusions: for a better control of rheumatic diseases requires a strategy of articulation where the strengths of primary, secondary and tertiary prevention are exploited, where the professionals in accordance with their competence execute actions that prevent the serious complications of these diseases and where properly treat infectious processes in particular, those produced by Streptococcus A, among others. Results of several clinical trials and therapeutic trials work with novel biological drugs, assessing their effectiveness, identifying adverse effects, assessing the risk-benefit ratio and the convenience of these forming part of the treatment scheme against various targets(AU)